Fri 23 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Non-Hodgkin’s Lymphoma (NHL) using a Closed Transduction System | King Faisal Specialist Hospital and Research Centre | Completed | CD19-CART | 1 | 2191301 | KFSH&RC-R |
| Phase I/II Study of a Lentigen® CD19 Chimeric Antigen Receptor (CAR) T Cells in Adult patients with relapsed/refractory CD19 Positive Acute Lymphoblastic Leukemia (ALL) using a Closed Transduction System | King Faisal Specialist Hospital and Research Centre | Completed | CD19-CART | 1/2 | 2191207 | KFSH&RC-R |
| Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) | Pfizer | Ongoing | PF-07055480 (formerly SB-525) | 3 | C3731003 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) | Pfizer | Ongoing | PF-06838435 | 3 | C0371002 | KFSH&RC-R |
| "Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS" | Eagle Pharmaceuticals | Completed | Dantrolene | 2 | EGL-4104-C-1502 | KFMC |
| Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML. | King Fahad Medical City | Ongoing | Vidaza | 2 | Version 1.1 | KFMC |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations | PSCDR | Completed | rAAV2 | 1 | rAAV2-VMD2-hMERTK | KFSH & RC-R |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |
| Perioperative Ischemic Evaluation-3 Tril (POISE-3) | KAIMRC | Ongoing | tranexamic acid | 3 | CT18/008/J | King Abdulaziz Medical City NG (Riyadh) |
| "Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation " | Novartis | Ongoing | deferasirox | 2 | CICL670FIC05 | KAUH-J |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.